TPIV Description — Marker Therapeutics Inc
Marker Therapeutics is a clinical-stage immuno-oncology company. Co. focuses on the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, as well as develops DNA expression technology. Co. is developing vaccines that target candidate breast cancer(s), colorectal cancer(s), ovarian cancer(s) and non-small cell lung cancer(s). Co.'s three primary technology platforms include: a licensed vaccine for the treatment of HER2/neu+ breast cancer; a licensed vaccine for treating breast and ovarian cancers; and a wholly owned DNA expression vaccine technology (Polystart) for treating various cancers or infectious disease.